Insider Trading Activity For Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Mark Sabag , EVP of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reportedly Sold 5,050 shares of the company’s stock at an average price of 19.68 for a total transaction amount of $99,384.00 SEC Form
Insider Trading History For Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Analyst Ratings History For Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
- On 3/2/2016 Nomura Reiterated Rating Neutral with a price target of $73.00
- On 4/19/2016 Canaccord Genuity Reiterated Rating Buy
- On 9/29/2016 OTR Global Initiated Coverage of rating Positive
- On 2/28/2017 Argus Downgraded rating Buy to Hold with a price target of $59.35 to $31.90
- On 8/3/2017 CIBC Reiterated Rating Outperform to Market Perform
- On 9/6/2017 JMP Securities Boost Price Target of rating Underperform with a price target of $13.00 to $14.00
- On 9/12/2017 Jefferies Group Lower Price Target of rating Hold with a price target of $21.00 to $18.50
Dividend Information For Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) pays an annual dividend of $0.72 with a yield of 3.55% and an average dividend growth of -14.40% (3 Year Average).
Dividend History For Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Recent Trading Activity for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Shares of Teva Pharmaceutical Industries Ltd closed the previous trading session at 20.15 down -0.75 3.57% with 20.864999771118164 shares trading hands.